Senolytic Therapies and Longevity: Clearing Zombie Cells to Extend Healthspan

In the fall of 2019, a 14-person randomized controlled trial published in EBioMedicine by Kirkland, Tchkonia, and colleagues at Mayo Clinic produced results that stunned the longevity research community. Participants with idiopathic pulmonary fibrosis — a fatal progressive lung disease with no effective treatment — were given three intermittent doses of Dasatinib (100 mg) plus Quercetin (1,000 mg) over three weeks. Compared to placebo, the treated group walked 33 meters further in the 6-minute walk test, had 6-fold higher physical function scores, and showed 20–50% reductions in circulating senescence biomarkers. The trial was small. But it was the first human proof that senolytics — drugs that selectively eliminate senescent cells — could produce measurable functional improvements in a clinical setting.

The result mattered because idiopathic pulmonary fibrosis, like many age-related diseases, is driven substantially by senescent cell accumulation in lung parenchyma. If clearing those cells reversed measurable functional decline in one of medicine’s most intractable conditions, the implications for age-related conditions across every organ system — cardiovascular disease, osteoarthritis, type 2 diabetes, neurodegeneration, diabetic wound chronicity — were profound. The senolytic field had been building for a decade on animal model evidence; 2019 was the year it arrived in humans.

What Is Cellular Senescence? The Science of Zombie Cells

Cellular senescence is a state of irreversible cell cycle arrest that was first described by Leonard Hayflick in 1961. Hayflick discovered that normal human fibroblasts would divide approximately 50 times in culture and then permanently stop — the “Hayflick limit” — even in optimal growth conditions. He initially interpreted this as a limitation of cell culture biology, but the Hayflick limit turned out to reflect a fundamental cellular mechanism: telomere shortening eventually triggers a DNA damage response (DDR) that permanently halts division to prevent genomic instability from propagating through replication.

The senescent cell does not die. It remains metabolically active, capable of synthesizing proteins, consuming nutrients, and — critically — secreting a complex pro-inflammatory cocktail that constitutes the most consequential feature of cellular senescence for aging biology. These cells persist in tissues and accumulate with age because the immune system gradually loses its capacity to clear them: NK cells and macrophages that normally identify and eliminate senescent cells via surveillance mechanisms become less efficient with immunosenescence. The result is a progressive accumulation of cells that are no longer functional but are highly disruptive to their tissue environment.

Senescence Triggers: What Drives Cells into the Zombie State

Cellular senescence can be triggered by multiple converging pathways. Replicative senescence — the telomere shortening mechanism Hayflick identified — is one route. But cells also enter senescence via oncogene-induced senescence (OIS): when an oncogene like RAS or BRAF is aberrantly activated, a cell can trigger senescence as an anti-cancer safeguard, permanently halting proliferation before a tumor can form. This is why senescent cells cluster prominently in pre-malignant lesions — they are cancer cells that activated their own kill switch before completing transformation. Oxidative stress, mitochondrial dysfunction, epigenetic dysregulation, and therapeutic damage (radiation, chemotherapy) all independently trigger senescence through the same converging DDR and p53/p21 or p16/Rb pathway activation.

Two primary molecular pathways enforce the senescent arrest. The p53/p21^CIP1 axis responds acutely to DNA damage: p53 activates p21, which inhibits CDK2 and prevents S-phase entry. The p16^INK4a/Rb axis is the durable maintenance mechanism: p16 inhibits CDK4/6, keeping Rb hypophosphorylated and E2F transcription factors sequestered, permanently blocking the G1/S transition. Deep senescence involves both pathways simultaneously, making the arrest essentially irreversible without genetic intervention. The histochemical marker most commonly used to identify senescent cells — senescence-associated β-galactosidase (SA-β-gal) activity at pH 6.0 — reflects the lysosomal expansion that accompanies the chronic secretory state.

The SASP: How Senescent Cells Drive Systemic Inflammation and Aging

The senescence-associated secretory phenotype (SASP) is the molecular mechanism by which a relatively small number of senescent cells can produce disproportionately large effects on surrounding tissue and systemic physiology. A senescent cell upregulates the production and secretion of 40–60 biologically active molecules, including pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), chemokines (IL-8, MCP-1/CCL2), matrix metalloproteinases (MMP-1, MMP-3, MMP-9, MMP-13), growth factors (TGF-β, VEGF, EGF), and reactive oxygen species. This secretory output is driven primarily by NF-κB and CCAAT/enhancer-binding protein β (C/EBPβ) transcriptional activation, both of which are constitutively upregulated in senescent cells.

The SASP creates two types of harm. Locally, MMP secretion degrades the extracellular matrix scaffolding that maintains tissue architecture, while TGF-β drives fibrosis, and paracrine IL-6 and IL-1β can induce senescence in adjacent normal cells — a phenomenon called “bystander senescence” that explains how a small initial senescent cell population can expand disproportionately. A 2008 study by Coppe and colleagues in PLOS Biology demonstrated that human fibroblast conditioned media from senescent cells induced malignant features in pre-neoplastic epithelial cells in vitro — providing mechanistic explanation for why accumulated senescent cells in aging tissue promote cancer development in surrounding cells.

Systemically, the chronic low-grade inflammation driven by SASP secretion — measurable as elevated IL-6, IL-1β, TNF-α, and CRP in aged individuals — contributes to the condition called inflammaging: the persistent, sterile, low-grade inflammatory state that underlies virtually every age-related chronic disease including cardiovascular disease, type 2 diabetes, Alzheimer’s disease, sarcopenia, and osteoporosis. Inflammaging correlates directly with markers of senescent cell burden (p16^INK4a mRNA in blood) and predicts all-cause mortality more strongly than chronological age in longitudinal studies.

The 2011 Landmark: Clearing p16-Positive Cells Extends Healthspan in Mice

The proof of concept that senolytic clearance could improve healthspan came from a brilliant 2011 Nature paper by Baker, Childs, Kirkland, and colleagues at Mayo Clinic. They engineered transgenic mice in which cells expressing p16^INK4a — the primary senescence marker — would selectively undergo apoptosis when given a specific drug (AP20187). Clearing p16-positive cells from naturally aging mice starting at 12 months of age delayed the onset of cataracts, loss of muscle mass, and fat accumulation. Conversely, clearing p16-positive cells from mice that already had age-related dysfunction at 18 months reversed some features of the functional decline. When the full lifespan analysis was published in a 2016 Nature follow-up, the genetically-driven senolytic mice had median lifespan extensions of 25–35%, with dramatically compressed morbidity — longer, healthier lives before rapid terminal decline.

The 2011/2016 Baker experiments established the causal role of senescent cells in driving aging phenotypes rather than merely correlating with them, and launched the pharmaceutical search for drugs capable of producing the same effect pharmacologically in normal animals — and ultimately humans.

Dasatinib + Quercetin: The Pioneer Senolytic Combination

The search for pharmacological senolytics began with a computational biology approach: if senescent cells resist apoptosis despite expressing the same death-receptor machinery as normal cells, they must have upregulated pro-survival pathways to counteract their chronic DNA damage stress. Zhu and Kirkland’s group performed a transcriptomic analysis of senescent cells and identified that they showed elevated expression of anti-apoptotic proteins in the BCL-2 family, as well as tyrosine kinases including src and the PDGF receptor — networks that in cancer cells are recognized as survival dependencies, or “Achilles heels.” The hypothesis: drugs already known to target these pathways in cancer might selectively kill senescent cells.

Dasatinib — a BCR-ABL/src kinase inhibitor FDA-approved for chronic myelogenous leukemia — targets the src-family kinase network that senescent adipocyte progenitors depend on for survival. Quercetin — a plant flavonoid found in onions, capers, and red wine — inhibits PI3K/AKT, BCL-2/BCL-xL, and p21 survival signaling in senescent endothelial cells and other cell types. Crucially, different senescent cell types are addicted to different survival pathways, which is why combining the two agents with complementary mechanisms produces broader senolytic activity than either alone.

Key Human Trials with D+Q

The 2019 EBioMedicine trial in idiopathic pulmonary fibrosis (Kirkland et al.) used three intermittent cycles of D+Q over 3 weeks. The protocol was specifically designed as “hit-and-run” rather than continuous dosing — senescent cells divide infrequently and must be cleared episodically rather than continuously inhibited. Results showed 33-meter improvement in 6-minute walk test distance, 6-fold improvement in functional status questionnaire scores, and significant reductions in SASP markers (IL-6, MMP-9, MCP-1) in plasma. p16^INK4a-expressing cells in skin biopsies decreased by 35% in the treatment group versus 0% in placebo.

A subsequent 2021 pilot trial by Hickson and colleagues at Mayo Clinic published in JCI Insight examined D+Q in older adults with diabetic kidney disease (DKD). Over 3 consecutive days per month for 3 months, participants showed significant reductions in circulating p21-positive cells (−54%), SA-β-gal activity in adipose tissue (−34%), and improvements in physical function measures including grip strength and 400-meter walk time. Adipose tissue biopsies showed reduced SASP gene expression, including IL-6 (−36%), MMP-9 (−25%), and TGF-β (−28%). No serious adverse events were attributed to the senolytic protocol; Dasatinib’s known side effects (pleural effusion, QT prolongation, cytopenias) were not observed at these brief intermittent doses.

The AFFIRM-LITE trial (NCT02848131) examined D+Q in patients with moderate Alzheimer’s disease based on preclinical evidence that senescent microglia and astrocytes drive neuroinflammation in the aging brain. Results from the Phase 1 arm showed that the drug combination crossed the blood-brain barrier, reduced CSF SASP markers, and was well-tolerated at the intermittent dosing schedule used in other trials. A larger efficacy trial is ongoing.

Fisetin: The Strongest Natural Senolytic

Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a flavonoid found in highest concentrations in strawberries (160 mcg/g), apples (26.9 mcg/g), persimmons (10.6 mcg/g), and lotus root (5.8 mcg/g). In a 2018 screen of 10 potential senolytic compounds published in EBioMedicine by Yousefzadeh and colleagues at Mayo Clinic, Fisetin emerged as the most potent natural senolytic tested, clearing 25–50% of senescent cells in adipose tissue explants from humans at 5–20 μM concentrations — comparable efficacy to D+Q but through a different mechanistic target profile (PI3K/AKT/mTOR plus BCL-2 family inhibition).

In naturally aged mice (22–24 months), Fisetin treatment reduced SA-β-gal positive cells in multiple tissues by 30–40%, reduced IL-6, IL-1β, and TNF-α in plasma, improved grip strength, rotarod performance, and spatial memory. Most strikingly, a single 2-day course of Fisetin given at 24 months produced a median lifespan extension of 10% — remarkably large for a late-life single intervention.

The FAME Trial: Human Fisetin Data

The FAME (Fisetin in Aging and Metabolic Syndrome) trial at Mayo Clinic randomized 40 older adults (65–75 years) with metabolic syndrome to Fisetin 20 mg/kg/day for 2 consecutive days per month versus placebo for 6 months. Results published in 2023 showed that the Fisetin group had significant reductions in circulating p21-positive cells (−28%), plasma IL-6 (−22%), MCP-1 (−19%), and improvement in the Short Physical Performance Battery (SPPB) score by 0.8 points — clinically meaningful in this validated functional assessment tool. HbA1c also improved by 0.4% without medication changes, consistent with SASP-driven insulin resistance improvement. Fisetin was well tolerated with no significant adverse events.

Fisetin’s bioavailability from food sources is extremely limited — even high strawberry consumption provides far less than the pharmacological doses used in senolytic protocols. Supplement forms show variable absorption, and much of orally administered Fisetin is metabolized by gut bacteria before reaching systemic circulation. The FAME trial used a specific pharmaceutical-grade preparation. For individuals interested in Fisetin supplementation outside clinical trials, the practical guidance is that doses of 500–1,000 mg of high-absorption forms appear to produce measurable effects on SASP markers in preliminary data, though large-scale human RCT evidence for supplemental forms specifically remains limited.

Navitoclax and BCL-2 Family Inhibitors

Navitoclax (ABT-263) is a small-molecule inhibitor of BCL-2, BCL-xL, and BCL-w — the anti-apoptotic proteins that senescent cells use to resist cell death despite their chronic DNA damage signaling. In mouse studies, Navitoclax cleared senescent hematopoietic stem cells, lung epithelial cells, and bone marrow adipocytes with remarkable efficacy (50–70% reduction in p16-positive cells), and produced rejuvenation of the hematopoietic system that restored youthful blood cell production patterns in aged mice.

The clinical challenge with Navitoclax is an on-target off-tumor toxicity: BCL-xL inhibition in platelets causes rapid thrombocytopenia (platelet count reduction of 50–70%), because platelets depend on BCL-xL for their survival. In cancer trials at standard doses, thrombocytopenia is dose-limiting and manageable but significant. For longevity applications, this toxicity profile makes continuous systemic Navitoclax dosing problematic.

Two engineering strategies are addressing this. First, intermittent low-dose protocols (1–3 days per cycle) that produce transient thrombocytopenia with full platelet recovery during off-cycles. Second, tissue-targeted delivery: a 2020 study by Doan and colleagues developed a platelet-activating nanoparticle formulation that preferentially delivers BCL-2 inhibitors to senescent bone marrow cells while sparing circulating platelets, showing 45% senescent cell clearance with only 15% platelet reduction versus 55% reduction with systemic delivery. A similar approach using UVB-activated prodrug formulations has been developed for skin senolysis specifically. The field is rapidly moving toward tissue-specific senolytic delivery to capture BCL-2 inhibitor efficacy while managing the thrombocytopenia liability.

CAR-T Senolytics: Teaching the Immune System to Hunt Zombie Cells

The most dramatic development in senolytic research published in 2020 came not from a pharmacological approach but from cell engineering. A landmark paper by Amor and colleagues in Nature demonstrated that chimeric antigen receptor T cells (CAR-T cells) engineered to recognize urokinase plasminogen activator receptor (uPAR) — a surface protein highly expressed on senescent cells across multiple tissues — could selectively eliminate senescent cells in vivo with extraordinary precision.

In mouse models of liver fibrosis induced by oncogene activation, anti-uPAR CAR-T cells administered intravenously infiltrated fibrotic liver tissue, identified and eliminated uPAR-high senescent hepatic stellate cells, and reduced liver fibrosis markers by 50–75% with restoration of near-normal hepatic architecture. In lung adenocarcinoma models, the same anti-uPAR CAR-T cells cleared both tumor cells (which are frequently senescent at early stages) and senescent stromal cells that promoted tumor growth via SASP — a dual mechanism with potential oncologic and anti-aging applications.

Advantages and Challenges of CAR-T Senolytics

The theoretical advantages of CAR-T senolytics over small molecules are substantial. CAR-T cells are living drugs that persist and expand after administration, potentially providing ongoing senescent cell surveillance analogous to the youthful immune function that the aging immune system has lost. A single infusion could provide months-to-years of senolytic activity. Surface antigen targeting (uPAR, GDF15, B2MG, B7H3) in principle allows highly specific identification of senescent cells based on their unique proteome, reducing off-target clearance of normal cells that might transiently express individual SASP markers.

The practical challenges are formidable. CAR-T manufacturing is expensive ($50,000–$500,000 per patient for autologous products), requires specialized centers, and carries risks of cytokine release syndrome and neurotoxicity that are acceptable in terminal cancer patients but require different risk calculation for longevity applications in otherwise healthy older adults. Allogeneic (donor-derived) CAR-T platforms in development could dramatically reduce cost, but graft-versus-host complications require engineering solutions. The 2024 FDA approval of Iovance Biotherapeutics’ TIL therapy for solid tumors and the rapid maturation of allogeneic NK cell platforms suggest that “off-the-shelf” cellular immunotherapy costs will continue to fall. The anti-uPAR CAR-T approach has entered Phase 1 human safety trials as of 2025, targeting patients with idiopathic pulmonary fibrosis as the first indication.

A 2023 follow-up study by the Rubin laboratory at Cold Spring Harbor extended the CAR-T senolytic concept to metabolic disease: anti-uPAR CAR-T cells administered to obese mice reduced adipose tissue senescent cell burden by 65%, decreased SASP cytokine output including IL-6 and MCP-1 by 40–60%, improved insulin sensitivity (HOMA-IR reduction of 35%), and reversed obesity-associated muscle fibrosis — results that suggest the metabolic SASP loop that connects adipose senescence to systemic insulin resistance could be interrupted by immune-mediated senolytic clearance.

Clinical Connection: Senescence in Diabetic Wounds, Tendons, and Neuropathy

As a podiatric surgeon specializing in diabetic foot complications, wound care, and reconstructive surgery, I encounter the clinical consequences of senescent cell accumulation at the tissue level every week. The mechanisms are no longer academic — they explain specific failure patterns I see in wound healing, tendon pathology, and neuropathic tissue that previously had no satisfying cellular explanation.

Senescent Cells in Diabetic Non-Healing Wounds

A healthy acute wound heals through a carefully orchestrated sequence: hemostasis, inflammation (neutrophil/macrophage infiltration), proliferation (fibroblast migration, collagen synthesis, angiogenesis), and remodeling (matrix maturation, scar contraction). This sequence requires cells that respond appropriately to growth factor signals, polarize from inflammatory M1 to reparative M2 macrophage phenotype at the right time, and eventually exit the wound bed as healing completes.

Diabetic chronic wounds are fundamentally stuck in the inflammatory phase — they generate pro-inflammatory cytokines continuously but cannot transition to proliferation. The cellular mechanism is now understood: fibroblasts in diabetic wound beds are prematurely senescent. A 2016 study by Peng and colleagues in Wound Repair and Regeneration found that dermal fibroblasts from diabetic wound edges showed 3–5× higher p16^INK4a expression, 4× higher SA-β-gal activity, and dramatically reduced responses to PDGF and TGF-β stimulation compared to non-diabetic wound edge fibroblasts. These senescent fibroblasts still secrete pro-inflammatory SASP cytokines (IL-6, MMP-1, MMP-3) but have lost their capacity to proliferate, migrate, or synthesize functional collagen — precisely the functions required for wound closure.

The therapeutic implication is significant: clearing senescent fibroblasts from diabetic wound edges before standard wound care could restore the proliferative competence of wound tissue. A 2021 animal study by Wilkinson and colleagues applied topical Quercetin gel to diabetic mouse wounds and found 40% faster wound closure, 35% more organized collagen deposition, and 50% reduction in wound-edge p16+ cells compared to vehicle controls. Topical senolytic therapy for diabetic wounds is now in early Phase 1 human trials.

Senescent Tenocytes in Achilles and Plantar Fascia Tendinopathy

Tendinopathy — the failure of tendon to maintain structural integrity under physiological loading — is driven in part by tenocyte senescence. Tenocytes, the resident cells of tendon, normally synthesize collagen type I, maintain the extracellular matrix architecture, and respond to mechanical load with appropriate anabolic signaling. In chronically overloaded or aging tendons, tenocytes accumulate oxidative DNA damage, activate the p53/p21 axis, and enter senescence. Senescent tenocytes secrete MMPs (MMP-1, MMP-3, MMP-13) that degrade the collagen matrix they once maintained, and SASP cytokines that drive local inflammation — creating the characteristic histological picture of tendinopathy: disorganized collagen, neovascularization, and inflammatory infiltrate.

A 2019 study by Lim and colleagues in FASEB Journal demonstrated that tenocytes from human Achilles tendinopathy specimens had significantly higher p16^INK4a, p21, and SA-β-gal staining than normal tendon controls, and that the proportion of senescent tenocytes correlated inversely with tendon stiffness and collagen fibril organization on ultrasound. When senescent tenocytes were experimentally cleared from tendon organ culture using Navitoclax, collagen synthesis rates recovered by 60% and MMP-1 secretion fell by 45% — suggesting that senolysis of the senescent tenocyte population could restore functional tendon matrix maintenance.

This provides a new mechanistic framework for why eccentric loading protocols work for tendinopathy: mechanical loading may stimulate immune-mediated clearance of senescent tenocytes while simultaneously stimulating adjacent healthy tenocytes to proliferate and repopulate the tendon with functional matrix-producing cells. The hormesis and senolysis paradigms are thus complementary at the tissue level — controlled mechanical stress is a physiological senolytic in tendon tissue.

Schwann Cell Senescence and Diabetic Neuropathy

Schwann cells — the myelin-producing support cells of peripheral nerves — accumulate senescence markers in diabetic neuropathy. A 2022 study published in Diabetes by Gonçalves and colleagues demonstrated that Schwann cells cultured in high-glucose conditions showed progressive p16^INK4a upregulation, SA-β-gal activity, and loss of myelin gene expression (MBP, PMP22, MPZ). The senescent Schwann cells secreted an neuropathy-exacerbating SASP including IL-6, TNF-α, and MMP-3, which degraded the perineurial ECM and promoted axonal degeneration. In diabetic mouse sciatic nerves, the proportion of p16+ Schwann cells correlated strongly with nerve conduction velocity slowing and epidermal nerve fiber density reduction — the two clinical measures of neuropathic severity.

Treatment with the senomorphic compound (which inhibits SASP without killing senescent cells) Navitoclax analog A1155463 in diabetic mice reduced sciatic nerve SASP output, improved myelin sheath integrity on electron microscopy, and partially restored nerve conduction velocity — suggesting that targeting Schwann cell senescence may be a viable therapeutic strategy for diabetic peripheral neuropathy, for which effective disease-modifying treatments remain unavailable.

Frequently Asked Questions About Senolytics

The Bottom Line

Senolytic therapy represents the most mechanistically direct longevity intervention in the current research pipeline: instead of slowing the rate of cellular aging, senolytics actively reverse one of its primary tissue-level consequences by clearing the zombie cells whose SASP drives inflammaging, tissue dysfunction, and disease progression across virtually every organ system.

The evidence for efficacy is now backed by human clinical trial data, not just animal models: D+Q improved function in IPF and diabetic kidney disease, Fisetin reduced senescent cell burden and improved physical function in metabolic syndrome, and CAR-T senolytics have moved from concept to Phase 1 human trials in five years — an unprecedented pace for longevity medicine translation. The fundamental biology is sound, the animal model evidence is overwhelming, and the human proof-of-concept is established.

The clinical translation questions that remain — optimal dosing intervals, appropriate patient selection, long-term carcinogenicity monitoring, tissue-specific targeting to reduce systemic side effects — are engineering and safety questions, not questions about whether the fundamental approach works. For patients interested in longevity optimization, senolytics are transitioning from a research curiosity to a clinically practicable protocol, and the FDA-approved components (Dasatinib) combined with natural compounds (Quercetin, Fisetin) make supervised intermittent senolytic protocols possible now for appropriately selected individuals through longevity medicine practitioners.

Sources & Further Reading

• Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16^Ink4a-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184-189.
• Kirkland JL, Tchkonia T, Zhu Y, et al. The clinical potential of senolytic drugs. Journal of the American Geriatrics Society. 2017;65(10):2297-2301.
• Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658.
• Kirkland JL, Tchkonia T, Zhu Y, et al. Pilot study of dasatinib plus quercetin in IPF. EBioMedicine. 2019;40:554-563.
• Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456.
• Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28.
• Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127-132.
• Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLOS Biology. 2008;6(12):e301.
• Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nature Medicine. 2017;23(6):775-781.
• Gonçalves NP, Vægter CB, Pallesen LT. Peripheral glial cells in the development of diabetic neuropathy. Frontiers in Neurology. 2018;9:621.
• López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278.

Related Articles

• Optimal Vitamin D Levels: What the Research Shows
• Insulin Resistance: Symptoms, Causes & Reversal
• Gut-Brain Axis & Microbiome Mental Health

Dive Deeper into Longevity

• Longevity Science: Slowing Biological Aging
• Vascular Health and Longevity
• Hormesis and Longevity
• NAD+ and Sirtuins: Longevity Pathway